학술논문

발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 34건 | 목록 1~10
Academic Journal
Kalinichev M; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland. Electronic address: mikhail.kalinichev@ipsen.com.; Girard F; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Haddouk H; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Rouillier M; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Riguet E; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Royer-Urios I; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Mutel V; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Lütjens R; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Poli S; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.
Publisher: Pergamon Press Country of Publication: England NLM ID: 0236217 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7064 (Electronic) Linking ISSN: 00283908 NLM ISO Abbreviation: Neuropharmacology Subsets: MEDLINE
Academic Journal
Kalinichev M; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland. Electronic address: mikhail.kalinichev@ipsen.com.; Donovan-Rodriguez T; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Girard F; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Haddouk H; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Royer-Urios I; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Schneider M; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.; Bate ST; Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Woolley Road Alconbury, Huntingdon PE28 4HS, UK.; Marker C; Algos Preclinical Serves Inc., 2848 Patton Road, Roseville, MN 55113, USA.; Pomonis JD; Algos Preclinical Serves Inc., 2848 Patton Road, Roseville, MN 55113, USA.; Poli S; Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland.
Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE
Academic Journal
Volpi C; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Mondanelli G; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Pallotta MT; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Vacca C; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Iacono A; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Gargaro M; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Albini E; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Bianchi R; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Belladonna ML; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Celanire S; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Mordant C; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Heroux M; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Royer-Urios I; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Schneider M; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Vitte PA; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Cacquevel M; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Galibert L; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Poli SM; Addex Therapeutics, Chemin des Aulx 14, 1228, Plans les Ouates, Geneva, Switzerland.; Solari A; Department of Economics, Management, and Statistics, University of Milano-Bicocca, Piazza dell'Ateneo Nuovo 1, 20126 Milano, Italy.; Bicciato S; Department of Life Sciences, Via G. Campi 287, University of Modena and Reggio Emilia, 41100 Modena, Italy.; Calvitti M; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Antognelli C; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Puccetti P; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Orabona C; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Fallarino F; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy.; Grohmann U; Department of Experimental Medicine, University of Perugia, Piazzale Gambuli 1, 06132 Perugia, Italy. Electronic address: ugrohmann@tin.it.
Publisher: Pergamon Press Country of Publication: England NLM ID: 0236217 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7064 (Electronic) Linking ISSN: 00283908 NLM ISO Abbreviation: Neuropharmacology Subsets: MEDLINE
Academic Journal
Kalinichev M; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.) mial@lundbeck.com sonia-maria.poli@addexpharma.com.; Le Poul E; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Boléa C; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Girard F; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Campo B; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Fonsi M; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Royer-Urios I; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Browne SE; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Uslaner JM; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Davis MJ; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Raber J; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Duvoisin R; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Bate ST; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Reynolds IJ; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).; Poli S; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.) mial@lundbeck.com sonia-maria.poli@addexpharma.com.; Celanire S; Addex Therapeutics, Plan-les-Ouates, Geneva, Switzerland (M.K., E.L.P., C.B., F.G., B.C., M.F., I.R.-U., S.P., S.C.); Merck Research Laboratories, West Point, Pennsylvania (S.E.B., J.M.U., M.J.D., I.J.R.); Oregon Health & Science University, Portland, Oregon (M.J.D., J.R., R.D.); and Huntingdon Life Sciences Ltd., Huntingdon Research Centre, Huntingdon, United Kingdom (S.T.B.).
Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE
Academic Journal
Kalinichev M; Addex Therapeutics SA, 12 Chemin des Aulx, CH-1228, Plan-les-Ouates, Geneva, Switzerland. mikhail.kalinichev@addexpharma.com; Rouillier MGirard FRoyer-Urios IBournique BFinn TCharvin DCampo BLe Poul EMutel VPoli SNeale SASalt TELütjens R
Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE
Academic Journal
Campo B; Addex Pharma SA, Geneva, Switzerland. brice.campo@addexpharma.com; Kalinichev MLambeng NEl Yacoubi MRoyer-Urios ISchneider MLegrand CParron DGirard FBessif APoli SVaugeois JMLe Poul ECelanire S
Publisher: Informa Healthcare Country of Publication: England NLM ID: 8406473 Publication Model: Print Cited Medium: Internet ISSN: 1563-5260 (Electronic) Linking ISSN: 01677063 NLM ISO Abbreviation: J Neurogenet Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Royer-Urios, I.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어